about
Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma.Prioritization in comparative effectiveness research: the CANCERGEN Experience.The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)Cost effectiveness of pharmacogenomics: a critical and systematic review.Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.Assessment of costs associated with adverse events in patients with cancer.Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver MetastasesThe impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors
P50
Q36016275-233E4B7C-F250-466E-8987-56555595B88FQ36311418-4C9CF163-541A-4B45-BDA0-8EC9712DB2A2Q36364504-02DC4987-E916-4BC2-89DA-164659035BD3Q37799352-05C2A9CE-D1B6-4C59-9F90-AD78206EE364Q38625524-AC93BE0D-737A-4253-A8C9-5CC701FED80CQ38884328-71EB06C4-31EB-49C8-BB8E-CC8E752DCE5DQ45942252-2B487D1A-7A2A-40AC-8ECE-73C4EBEAF8CFQ47656631-FBF47C9D-EC0A-41A0-AF8C-6E6845F50D69Q49307383-B20513F0-6406-49D9-9B08-96E373402368Q49942524-3E7E752F-8C16-47EA-A2E1-8470974D882EQ52587608-C11007F6-2B39-444B-BBCA-A1611BFDA69CQ52589868-A980D473-06BD-4108-9692-A2C6BA342F3AQ52682138-9323740F-B5AD-4EED-AD2D-688AB0EC4100Q87113035-DA7E7936-D81D-43A2-A49C-0F6A316A367AQ90059583-62393D2A-DA28-42C0-9CFB-8C48331B7FC0Q91393542-04939A72-CD1B-471B-81E2-E4688FE4933F
P50
description
investigador
@es
researcher
@en
name
William Wong
@en
type
label
William Wong
@en
prefLabel
William Wong
@en
P108
P31
P496
0000-0002-6054-278X